نتایج جستجو برای: vismodegib

تعداد نتایج: 334  

Journal: :Cancer biology & therapy 2016
Emil Lou Matthew Schomaker Jon D Wilson Mary Ahrens Michelle Dolan Andrew C Nelson

Medulloblastoma is an aggressive primitive neuroectodermal tumor of the cerebellum that is rare in adults. Medulloblastomas fall into 4 prognostically significant molecular subgroups that are best defined by experimental gene expression profiles: the WNT pathway, sonic hedgehog (SHH) pathway, and subgroups 3 and 4 (non-SHH/WNT). Medulloblastoma of adults belong primarily to the SHH category. Vi...

2017
Giles W. Robinson Sue C. Kaste Wassim Chemaitilly Daniel C. Bowers Stephen Laughton Amy Smith Nicholas G. Gottardo Sonia Partap Anne Bendel Karen D. Wright Brent A. Orr William C. Warner Arzu Onar-Thomas Amar Gajjar

The permanent defects in bone growth observed in preclinical studies of hedgehog (Hh) pathway inhibitors were not substantiated in early phase clinical studies of vismodegib in children. Consequently, vismodegib advanced into pediatric trials for malignancies suspected of being driven by aberrant activation of the Hh pathway. In one multicenter phase II trial, vismodegib was added to the therap...

Journal: :Clinical Cancer Research 2012

Journal: :Actas Dermo-Sifiliográficas (English Edition) 2014

Journal: :Swiss Medical Forum ‒ Schweizerisches Medizin-Forum 2014

2013
Muzafar A Macha Surinder K Batra Apar Kishor Ganti

Basal cell carcinoma (BCC) is the most common human malignancy. Recent advances in our understanding of the critical biologic pathways implicated in the development and progression of BCC have led to the development of the first molecular targeted therapy for this disease. The hedgehog pathway is mutated in virtually all patients with BCC and recent trials with vismodegib, an inhibitor of this ...

2015
Olga Vornicova Gil Bar-Sela

BCC: Basal cell carcinoma INTRODUCTION Basal cell carcinoma (BCC) is the most common form of skin cancer, making up approximately 80% of all nonmelanoma skin cancers. Traditional therapy includes various types of surgery (Mohs, cryosurgery, excision, electrodessication and curettage), topical therapies (5-fluorouracil, imiquimod), or radiation therapy. A new and effective treatment, vismodegib,...

2016
Anne Lynn S. Chang Sarah T. Arron Michael R. Migden James A. Solomon Simon Yoo Bann-Mo Day Edward F. McKenna Aleksandar Sekulic

BACKGROUND Aberrant activation of the Hedgehog (Hh) pathway is a key driver in the pathogenesis of basal cell carcinomas (BCCs), including patients with BCC nevus syndrome (BCCNS). It is unclear whether BCCs arising in patients with BCCNS respond differently to vismodegib than in patients without BCCNS. We examined the best overall response rate (BORR) and adverse events (AEs) of vismodegib in ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید